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Abstract
Background: Programmed cell death protein 1 (PD-1) plays an important role in immune response regulation as a
co-inhibitory signal during T cell activation. However, there is little known about the serum autoantibody profile of
PD-1 in systemic lupus erythematosus (SLE), a disease characterized by the breakdown of immune tolerance to
self-antigens and an excessive production of autoantibodies. Thus, we aim to investigate the serum levels and
function of anti-PD-1 in patients with new-onset SLE.
Methods: Serum levels of anti-PD-1 IgG and IgM isotypes were detected in new-onset SLE patients (n = 90),
rheumatoid arthritis (n = 50), primary Sjogren’s syndrome (n = 50), ankylosing spondylitis (n = 25), and healthy
controls (HC) (n = 80) using an enzyme-linked immunosorbent assay (ELISA). The correlation of anti-PD-1 with
clinical characteristics and laboratory parameters of patients with new-onset SLE was analyzed. The effects of
purified anti-PD-1 IgG from SLE patients on T cell proliferation were measured using flow cytometry.
Results: The data revealed increased levels of anti-PD-1 IgG, but not IgM, especially in new-onset SLE patients, and
the positive rate of anti-PD-1 IgG was 30 (33.3%). The level of anti-PD-1 IgG was closely associated with malar rash
(OR = 15.773), arthritis (OR = 22.937), serositis (OR = 16.008), hematological (OR = 35.187), renal (OR = 8.306), and
neurological involvement (OR = 37.282). Moreover, the serum levels of anti-PD-1 IgG were positively correlated with
the SLE disease activity index (SLEDAI) score (r = 0.296, p = 0.0046) and the erythrocyte sedimentation rate (ESR)
(r = 0.2446, p = 0.0201). In vitro examination showed that purified anti-PD-1 IgG obtained from SLE patients
enhanced T cell proliferation when co-cultured with dendritic cells (DCs).
Conclusions: The current study indicates, for the first time, that the serum levels of co-inhibitor autoantibodies
against PD-1 are elevated in new-onset SLE patients and are associated with disease activity in SLE. Autoantibodies
against PD-1, facilitating T cell proliferation, revealed a new insight into the function of negative regulation signals
involved in the pathogenesis of SLE.
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Background
Systemic lupus erythematosus (SLE) is a prototypical
autoimmune disease that typically manifests with symp-
toms including rash, arthritis, serositis, nephritis, and neu-
ropsychopathy [1]. It is characterized by a breakdown of
immune tolerance to self-antigens, leading to excessive
production of autoantibodies [2]. T cells in patients with
SLE display altered attributes and are the primary contrib-
utors to disease initiation and perpetuation, as they are
specialized for activating B cells and dendritic cells as well
as secreting cytokines [3]. Although the precise mecha-
nisms that facilitate the initiation of SLE-related pathology
remain unclear, there is an indication that, once immune
tolerance is compromised, T cells and B cells play import-
ant roles in the amplification and perpetuation of the
autoimmune and inflammatory responses [4].
Several lines of evidence have demonstrated that insuf-
ficient co-inhibition can lead to a loss of self-tolerance
and, thus, to autoimmunity, resulting in deleterious in-
flammation in and destruction of self-tissues mediated
by autoreactive T cells and autoantibodies [5]. Our previ-
ous study revealed a novel autoantibody against class A
scavenger receptors in SLE patients which contributes to
the breakdown of immune tolerance by the loss of the
ability to clear apoptotic cells [6].
Recently, much attention has been paid to pro-
grammed cell death protein 1 (PD-1, CD279), a surface
protein which belongs to the immunoglobulin superfam-
ily, and functions as an immunomodulatory molecule.
PD-1, binding with its ligand PD-L1, delivers inhibitory
signals to negatively regulate the immune response after
T cell activation, and thus, maintains the balance of
immune tolerance [7]. Upon PD-1 signals, antigen-
presenting cells can convert naive CD4+ T cells into
Foxp3+ induced regulatory T (iTreg) cells [8]. Numerous
studies have been reported that PD-1 and PD-L1 play an
important role in the pathogenesis of autoimmune dis-
eases in PD-1-deficient murine models, which present
lupus-like glomerulonephritis, arthritis, and fatal auto-
immune dilated cardiomyopathy [9–11]. In addition,
blockade of the PD-1/PD-L pathway could exaggerate or
accelerate the development of autoimmune diseases
such as diabetes [12] and experimental autoimmune en-
cephalitis [13]. Given the immunomodulatory properties
of PD-1 and PD-L, efforts have been made to elucidate
the functions of PD-1 and PD-L in SLE patients. Lower
PD-1 expression has been found on CD4+ T cells in SLE
patients and is correlated with PD-1 genotype, suggest-
ing a crucial role of PD-1 in SLE [14, 15]. Moreover,
elevated frequency of PD-L1-expressing neutrophils has
been reported in patients with SLE, and is correlated
with the disease activity and severity of SLE [16].
However, the serum profile of autoantibodies against
PD-1 in SLE remains to be determined.
In this study we aimed to investigate the serum levels
of autoantibodies against co-inhibitory PD-1 and their
impact on T cell proliferation in new-onset SLE patients
in vitro.
Methods
Patients and healthy controls
The study included 90 consecutive, untreated, new-onset
patients with SLE who fulfilled the American College of
Rheumatology (ACR) classification criteria for the diag-
nosis of SLE [17], and 50 patients with primary Sjogren’s
syndrome (pSS), 50 with rheumatoid arthritis (RA) and
25 with ankylosing spondylitis (AS) according to the
standard diagnostic criteria [18–20]. Finally, samples
from 80 sex- and age-matched healthy donors with nei-
ther autoimmune nor infectious diseases were collected
as healthy controls. Demographic data, clinical charac-
teristics, and laboratory findings of SLE patients were
collected. All of the sera samples were stored at -80 °C
until use. Disease activity was measured using the SLE
disease activity index 2000 (SLEDAI-2 K) [21]. The study
was performed in accordance with the Declaration of
Helsinki and the principles of Good Clinical Practice.
Biological samples were obtained under a protocol ap-
proved by the Institutional Research Ethics Committee
of Ruijin Hospital (ID: 2016-62), Shanghai, China. All
subjects signed written informed consent.
Production of recombinant human PD-1 extracellular
domain
The extracellular domain of the human PD-1 gene
(NP_005009.2) Leu24-Gln167 was synthesized by
General Biosystems Inc. (Morrisville, NC, USA). The
PD-1 extracellular domain gene was fused to the human
immunoglobulin (Ig)G1 Fc region at the N-terminus and
the 6xHis tag at the C-terminus using the OE-PCR
method. The PCR product was digested with BamHI
and XhoI, and cloned into the pCDNA3.4-Topo vector
(Invitrogen, Grand Island, NY, USA) under the CMV
promoter and mouse Ig-kappa signal peptide for high-
level secretion. The recombinant PD-1-nFc-His6 was
expressed in Expi293 cells by transient transfection using
ExpiFectamine reagent (Life Technologies, Carlsbad,
CA, USA). After transfection for 3 days, the culture
supernatant was collected and the recombinant protein
was purified using a protein A column (GE Healthcare,
Milwaukee, WI, USA). As a result of glycosylation, the
purified PD-1-nFc-His6, as a disulfide-linked homodi-
mer, migrated as an approximately 120 kDa protein in
nonreducing SDS-PAGE. The homodimer was incubated
with recombinant enterokinase (Novoprotein, Shanghai,
China) at 37 °C for 24 h, passed through the protein A
column to remove the Fc region, and exchanged to a
PBS buffer for storage at 4 °C. The concentration of
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recombinant PD-1-His6 was determined by bicinchoni-
nic acid (BCA) protein assay (Pierce Biotechnology,
Rockford, USA). The recombinant PD-1-His6 consisted
of 156 amino acids and, due to glycosylation, migrated
as an approximately 35 kDa protein in nonreducing
SDS-PAGE.
Detection of PD-1 autoantibodies
Antibodies against human PD-1 in the sera of SLE
patients, pSS patients, RA patients, AS patients and
healthy controls were determined by using an enzyme-
linked immunosorbent assay (ELISA). Ninety-six-well
high-binding plates (Corning, Corning, NY, USA) were
coated with recombinant human PD-1 extracellular
domain (1 μg per well) overnight at 4 °C in 0.05 mol/L
carbonate buffer sodium (PH = 9.6). The antigen-coated
wells were washed three times with PBST (PBS plus
0.05% Tween-20) and blocked with PBST containing 5%
bovine serum albumin (BSA) for 2 h at 37 °C. The block-
ing buffer was tapped off and washed as described above
before the addition of 100 ul of serum sample (1:100
diluted in 1% BSA). The PD-1 monoclonal antibody
(Novoprotein, Summit, NJ, USA) was used as a positive
control. Human sera were incubated for 2 h at room
temperature followed by incubation with HRP-conjugated
goat anti-human IgG and IgM (Abcam, Cambridge, UK)
for another 1 h at room temperature. Then, the plates
were washed and 100 ul of tetramethylbenzidine (TMB)
substrate solution was added. The color development was
stopped by the addition of 50 ul of 0.5 M H2SO4. Absorb-
ance was measured at a wavelength of 450 nm in a micro-
plate reader (Bio-Rad Laboratories, Richmond, CA, USA).
All samples and standards were run in duplicates and the
readings were performed in duplicates.
IgG purification
IgG was isolated from the sera of new-onset SLE pa-
tients with high levels of anti-PD-1 IgG according to the
ELISA assay by protein A agarose (Pierce, Rockford, IL,
USA). The isolates were examined for endotoxin con-
tamination using a limulus amoebocyte lysate (LAL)
assay (A&C Biological Ltd., Zhanjiang, China). The total
protein content was estimated using a BCA assay.
Purification of specific autoantibodies against PD-1
The purification of specific antibodies was performed ac-
cording to a previous report [22]. In brief, recombinant
human PD-1 was spotted onto a nitrocellulose filter and
incubated with the purified IgG from SLE patients. After
washing with PBST, the antibodies were eluted with
100 mM of glycine (pH = 2.8). The eluted antibodies
were immediately neutralized with 1 M of Tris-HCl
(pH = 8.0). Normal human IgG was purchased from
Millipore (Darmstadt, Germany). The purified PD-1
antibodies were concentrated with a final concentra-
tion of 1 mg/ml. After sterile filtration, the autoanti-
bodies were stored as small aliquot package in -80 °C.
Preparation of monocyte-derived dendritic cells (DCs)
Peripheral blood monocytes (PBMCs) were isolated from
the blood of three healthy volunteers using Ficoll density
gradient centrifugation (GE Healthcare). The CD14+
PBMCs were isolated by positive selection using CD14
microbeads (Miltenyi Biotec, Auburn, CA, USA)
according to the manufacturer’s instructions. The se-
lected cells were cultured in RPMI 1640 containing 10%
fetal calf serum (FCS; Gibco, Grand Island, NY, USA),
2 mM L-glutamine, 100 units/ml penicillin, 100 μg/ml
streptomycin and supplemented with 20 ng/ml of
granulocyte-macrophage colony-stimulating factor (GM-
CSF) and 20 ng/ml of interleukin (IL)-4 (R&D Systems,
Inc., Minneapolis, MN, USA) in a humidified 5% CO2 in-
cubator. On day 7, DCs were stimulated with 50 ng/ml of
lipopolysaccharide (LPS) for 24 h. The matured DCs were
labeled with anti-human CD80, CD86, and HLA-DR (BD
Biosciences Pharmingen, San Diego, CA, USA) and ana-
lyzed using a FACS Canto II instrument (BD Biosciences
Pharmingen). More than 90% of the cultured cells were
triple positive for CD80, CD86, and HLA-DR.
Preparation of autologous T cells
Autologous T cells were isolated from the PBMC of
three healthy volunteers on day 8. The CD3+ T cells
were isolated by positive selection using CD3 microbe-
ads (Miltenyi Biotec) according to the manufacturer’s in-
structions. CD3+ T cells were cultured in RPMI 1640
containing 10% FCS, 2 mM L-glutamine, 100 units/ml
penicillin, 100 μg/ml streptomycin and supplemented with
20 U/ml of IL-2 (R&D Systems, Inc.) and 0.5 ug/ml of
mouse anti-human CD3 (BD Biosciences Pharmingen) for
3 d. Activated T cells were stained with PE-labeling anti-
human PD-1 antibody (BD Biosciences Pharmingen) and
examined using a FACS Canto II instrument.
T cell proliferation assay
For the proliferation assay, 1 × 105 T cells were labeled
with 10 μM of CFSE (Sigma-Aldrich, St. Louis, MO,
USA) in 100 μl pre-cold PBS, followed by incubation in
37 °C for 10 min and neutralization with pre-cold fetal
bovine serum according to the manufacturer's in-
structions (Molecular Probes, Leiden, Netherlands).
CFSE-labeled T cells were incubated with fresh medium
containing purified human PD-1 antibodies from SLE
patients or normal human IgG for 1 h at 37 °C. After
being co-cultured with 1 × 104 DCs in round-bottom
96-well tissue culture plates (Corning) for 72 h, cells were
collected. PerCP Cy5.5-conjugated anti-human CD4 anti-
body was used for CD4 T cell staining according to the
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manufacturer’s protocols. Each experiment was pre-
formed, duplicated and analyzed using a FACS Calibur
cytometer and analyzed using FlowJo software (Tree Star
Inc., Ashland, OR, USA).
Statistics
For continuous variables, comparisons were carried out
using an independent t test for two independent sam-
ples, a Mann-Whitney U test for non-normal data, and a
paired t test for matched samples. Categorical variables
were compared by the chi-square test or Fisher’s exact
test. Correlations between groups were evaluated by the
Spearman test. Results are expressed as the mean ±
standard deviation (SD) of three independent experi-
ments. Multivariate analysis was performed in order to
identify the independent factors that are positively
associated with the dependent variable. To control for
possible confounding parameters, various multivariate
logistic regression models were designed. The magnitude
of each factor was expressed as an odds ratio (OR). A
p value less than 0.05 was considered statistically signifi-
cant. Graphs were drawn using Graphpad Prism (version
6, Graphpad Software, San Diego, CA, USA). Data were
analyzed using the IBM SPSS software package for
Windows (version 23.0; IBM Corp., Armonk, NY, USA).
Results
Characteristics of the study population
A total of 90 patients diagnosed with SLE, 50 patients with
pSS (mean age ± SD, 32.39 ± 7.6 years; female/male, 41/9),
50 patients with RA (mean age ± SD, 30.87 ± 8.1 years;
female/male, 42/8), 25 patients with AS (mean age ± SD,
30.19 ± 7.1 years; female/male, 20/5) and 80 healthy
donors (mean age ± SD, 31.45 ± 8.9 years; female/male,
68/12) were included in this study. There were no signifi-
cant differences between the groups with regard to age
and gender ratio. SLE disease activity was evaluated using
the systemic lupus erythematosus disease activity index
2000 (SLEDAI-2 K) [21]. The history, manifestation, and
autoantibody profile of SLE was collected for each patient.
Demographic and clinical data are summarized in Table 1.
Increased serum level of co-inhibitory PD-1
autoantibodies in new-onset SLE patients
For each individual, the optical density (OD) values at
450 nm for anti-PD-1 IgG and IgM were examined using
ELISA. As shown in Fig. 1, the OD value of anti-PD-1
IgG in sera from SLE patients was significantly higher
than in healthy controls (HC, p < 0.001), RA group
(p < 0.001), pSS group (p < 0.01), and AS group (p < 0.001)
whereas the IgM isotype of PD-1 antibodies showed no
significant difference between any two groups. Next, we
defined the positive sample as the ratio of the positive and
negative optical densities (P/N) greater than 2.1, according
to previous work [23]. Among 90 patients with SLE, the
positive rate of anti-PD-1 IgG and IgM was 30 (33.3%) and
18 (5%), respectively.
Association between anti-PD-1 IgG and clinical features of
new-onset SLE patients
Table 2 shows the correlation of anti-PD-1 with the
clinical parameters of patients with new-onset SLE.
The level of anti-PD-1 is closely associated to malar rash
(OR = 15.773; 95% CI 3.065–81.186), arthritis (OR = 22.937;
95% CI 4.619–113.9), serositis (OR = 16.008; 95% CI 2.119–
120.967), hematological (OR = 35.187; 95% CI 6.459–
191.679), renal (OR = 8.306; 95% CI 1.323–52.132), and
neurological involvement (OR = 37.282; 95% CI 1.497–
928.697). However, no association was observed between
anti-PD-1 and the clinical features of discoid rash, oral
ulcer, photosensitivity, vasculitis, or Raynaud’s phenomenon
(p > 0.05). These findings suggest that anti-PD-1 might play
Table 1 The clinical characteristics of the new-onset untreated
SLE patients (n = 90)
Variable SLE patients
Gender (female/male, n) 76/14
Age (mean ± SD, year) 33.1 ± 9.8
Disease duration (mean ± SD, days) 72.0 ± 53.0
SLEDAI (mean ± SD) 12.9 ± 7.9
Disease activity
SLEDAI ≤ 8, (n, %) 40, (44.4)
SLEDAI > 8, (n, %) 50, (55.6)
Disease manifestations
Arthritis (n, %) 41, (45.6)
Rash (n, %) 43, (47.8)
Oral ulcer (n, %) 11, (5.0)
Serositis (n, %) 16, (17.8)
Photosensitivity (n, %) 14, (15.6)
Raynaud’s phenomenon (n, %) 5, (5.6)
Hematological (n, %) 46, (51.1)
Lupus nephritis (proteinuria ≥ 0.5 g/24 h) (n, %) 21, (23.3)
Neuropsychiatric manifestations (n, %) 8, (8.9)
Autoantibody profile
Anti-dsDNA + (n, %) 75, (83.3)
Anti-Sm + (n, %) 21, (23.3)
Anti-SSA + (n, %) 42, (46.7)
Anti-SSB + (n, %) 13, (14.4)
Anti-U1RNP + (n, %) 29, (32.2)
Anti-Rib-P + (n, %) 15, (16.7)
Anti-nucleosome-A + (n, %) 36, (40.0)
SLE systemic lupus erythematosus, SD standard deviation, SLEDAI-2 K SLE
disease activity index 2000
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a critical role in the occurrence of systematic clinical
features.
Cross-correlation analysis for anti-PD-1 IgG with disease
activity
Next, in order to evaluate the relationship of serum anti-
PD-1 levels and disease activity, we first analyzed the
correlation between anti-PD-1 IgG, the SLEDAI score,
and laboratory parameters including erythrocyte
sedimentation rate (ESR), anti-dsDNA, and antinuclear
antibodies (ANA). The results show that the serum
levels of anti-PD-1 IgG are positively correlated with
SLEDAI score (r = 0.296, p = 0.0046) and ESR (r = 0.2446,
p = 0.0201), whereas no statistically significant correlation
was observed for anti-PD-1 IgG with anti-dsDNA (r =
0.0398, p = 0.9563), ANA (r = 0.0164, p = 0.8783) (Fig. 2),
as well as C-reactive protein (CRP) and complement C3
and C4 levels (p > 0.05, data not shown). Furthermore, we
classified SLEDAI scores into four equal groups (group I,
SLEDAI = 0–4; group II, SLEDAI = 5–9; group III, SLE-
DAI = 10–14; group IV, SLEDAI > 14) and found that the
serum levels of anti-PD-1 IgG in group I patients were
significantly lower than levels in group II (p = 0.04) and IV
(p = 0.001), but not group III (p = 0.151) (Additional file 1:
Figure S1). Finally, we also analyzed the correlation be-
tween anti-PD-1 and other laboratory findings. As shown
in Fig. 3, the serum titer of anti-PD-1 IgG is not sig-
nificantly different between patients with seropositive and
seronegative autoantibodies including anti-Sm, anti-
U1RNP, anti-SSA, and anti-SSB. These findings indicate
that the serum level of autoantibodies against PD-1 might
be a potential marker for SLE disease activity.
Purified autoantibodies against PD-1 from SLE patients
promote CD4+ T cell proliferation
Given that co-inhibitor PD-1/PD-L1 is crucial in regulat-
ing T cell activation [7], we therefore explored the effect
of purified anti-PD-1 from SLE patients on T cell prolif-
eration using a DC and T cell co-culture system. It is
well known that PD-1 is expressed on activated T cells.
We first examined the PD-1 levels on the surface of
CD4+ T cells activated by anti-CD3 (0.5 ug/ml) for 3 d.
The results showed that PD-1 is expressed after the acti-
vation of the T cells, while there was no PD-1 detected
on the surface of unstimulated T cells (Fig. 4a, b), which
is consistent with previous findings [24].
Next, we purified PD-1 autoantibodies from SLE patients
with high levels of anti-PD-1 IgG and carried out a prolif-
eration assay using a T and DC cell co-culture system. The
results showed that, compared to the IgG control group, T
cell proliferation was enhanced after blocking the PD-1
Fig. 1 Elevated levels of PD-1 antibodies (IgG isotype) in new-onset SLE patients. The serum levels of PD-1 autoantibodies IgG isotype (a) and IgM
isotype (b) from SLE patients (◆, n = 90), pSS patients (▲, n = 50), RA patients (■, n = 50), AS patients (▼, n = 25) and healthy controls (HC, ●, n = 80).
All standards and samples were run in technical replicates, and readings were performed in duplicates. The optical density (OD) value for each
individual is represented as a single point. Values represent the means ± SD. **p < 0.01, ***p < 0.001. AS ankylosing spondylitis, Ig immunoglobulin,
HC healthy control, PD-1 programmed cell death protein, SS Sjogren’s syndrome, RA rheumatoid arthritis, SLE systemic lupus erythematosus 1
Table 2 Association of anti-PD1 with clinical features of
new-onset SLE patients
Clinical manifestations p value Odds ratio 95% CI
Malar rash 0.001 15.773 3.065–81.186
Discoid rash 0.077 12.688 0.762–211.274
Arthritis <0.001 22.937 4.619–113.9
Oral ulcer 0.279 3.830 0.336–43.256
Photosensitivity 0.477 4.042 0.086–189.971
Vasculitis 0.216 4.851 0.398–59.109
Raynaud’s phenomenon 0.657 2.266 0.061–84.212
Serositis 0.007 16.008 2.119–120.967
Hematological involvement <0.001 35.187 6.459–191.679
Renal involvement 0.024 8.306 1.323–52.132
Neurological involvement 0.027 37.282 1.497–928.697
PD-1 programmed cell death protein 1, SLE systemic lupus erythematosus
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function with PD-1 autoantibodies from SLE patients and
commercial monoclonal PD-1 antibody (Fig. 4c and d).
These data indicate that self-reactive autoantibodies against
co-inhibitor PD-1 may contribute to the dysregulated T cell
hyperproliferation observed during SLE pathogenesis.
Discussion
Recent studies have demonstrated that immune check-
points, such as the PD-1 pathway, are vital regulatory
pathways for maintaining the homeostasis and tolerance
of the immune system [5, 25]. Selective blockade of
Fig. 2 Correlation between anti-PD-1 IgG and SLE disease-related indicators including SLEDAI score (a), ESR (b), anti-dsDNA (c), and ANA (d).
ANA antinuclear antibodies, ESR erythrocyte sedimentation rate, Ig immunoglobulin, PD-1 programmed cell death protein 1, SLEDAI-2 K SLE
disease activity index 2000
Fig. 3 The correlation analysis of serum anti-PD-1 IgG levels between patients with seropositive and seronegative autoantibodies including
anti-Sm (a), anti-U1RNP (b), anti-SSA (c), and anti-SSB (d). No significant difference was found in the four groups. Ig immunoglobulin, PD-1
programmed cell death protein 1
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immune checkpoints reinforce antitumor immunity, in
turn resulting in autoimmune diseases such as SLE and
rheumatoid arthritis [25, 26]. PD-1, a member of the B7
receptor family, has been reported to be expressed
mainly on activated T cells, B cells, and monocytes
[24, 27, 28]. After binding with PD-L1, PD-1 delivers a
negative signal which inhibits immune responses via
downregulating T cell activation, and, thus, affecting per-
ipheral T cell tolerance.
PD-1 is the most studied co-inhibitory receptor in
SLE. The polymorphism of PD-1 has been established to
be associated with susceptibility to SLE [29–31]. In par-
ticular, T cell proliferation was increased in homozygous
PD1.3 (A/A) SLE patients, while it was significantly re-
duced in heterozygous and wild-type (G/G) patients and
healthy controls [15]. Previous studies revealed that a
lack of PD-1 or PD-1 blockade by anti-PD-1 commercial
antibodies result in an exacerbation of T cell-mediated
immunopathology in various disease models, including
SLE. Furthermore, PD-1 knockout mice developed
lupus-like autoimmune symptoms spontaneously and
had significantly increased levels of immunoglobulin [9].
There was an interesting finding that T cell proliferation
could be increased by adding sera from active SLE pa-
tients with unknown mechanism [15]. Our results reveal,
for the first time, anti-PD-1 antibody in sera from SLE
patients promoting the T cell proliferation, indicating a
pathogenic role for anti-PD-1 antibodies in SLE.
Recently, the anti-PD-1 antibody has been suggested
as a new serological marker for type 1 autoimmune
hepatitis [32]. However, there is still little known about
the expression level and function of self-reactive auto-
antibodies against PD-1 in SLE patients. In the present
study, autoantibodies against PD-1 IgG and IgM were
found in SLE patients (33.3% and 5%, respectively) spe-
cifically. In addition, our data also indicated that serum
levels of anti-PD-1 IgG are positively correlated with
specific clinical symptoms and disorders including malar
rash, arthritis, and serositis, as well as multiple organ
involvement including hematologic disorders, renal
diseases, and neurological dysfunctions (as shown in
Table 2). Our results also revealed that the level of anti-
PD-1 was closely associated with the disease activity
indicators of SLE patients including the SLEDAI score
and ESR. Furthermore, when we stratified patients
according to their SLEDAI score, we found that the
levels of anti-PD-1 IgG in new-onset SLE patients with
SLEDAI scores of 0–4 were significantly lower compared
with patients with SLEDAI scores of 5–9 and >14. These
results suggest that serum levels of anti-PD-1 IgG might
be a helpful indicator to evaluate the disease activity of
SLE patients.
Fig. 4 PD-1 autoantibodies increased T cell proliferation. Autologous T cells and DCs were co-cultured for 72 h. a, b PD-1 expression on T cells
activated by anti-CD4 detected by flow cytometry. c The division of CFSE-labeled CD4+ T cells determined by flow cytometry. The data represent
one of three independent experiments. d The statistic graph of three experiments. Values represent the means ± SD. *p < 0.05, **p < 0.01,
***p < 0.001. DCs dentritic cells, Ig immunoglobulin, mAb monoclonal antibody, PD-1 programmed cell death protein 1
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The role of the PD-1 pathway in maintaining immune
tolerance at the level of DC-T cell interactions has been
well established [33], and persistent activation of self-
reactive CD4+ T cells is a pathogenic hallmark of
autoimmune diseases such as SLE [3]. Considering the
elevated levels of PD-1 autoantibodies in SLE patients,
we further examined the function of these self-reactive
antibodies extracted from the sera of SLE patients in
promoting CD4+ T cell proliferation. Our results showed
that the proliferation of DC-activated CD4+ T cells was
enhanced after incubation with PD-1 autoantibodies, in-
dicating that the co-inhibitory PD-1 pathway is blocked
by the autoantibody against PD-1 pathologically in SLE
patients. Our data demonstrate that the dysfunction of
PD-1, beyond the polymorphism, owing to the self-
reactive autoantibodies.
It has been demonstrated that PD-1 knockout in C57
BL/6 mice resulted in the development of lupus arthritis
and glomerulonephritis, which indicated the important
role of PD-1 in maintaining the homeostasis of auto-
immunity [12]. Moreover, lower expression of PD-1 on
PBMCs and CD4 + CD25+ T cells have been found in
SLE patients [14, 15]. Combined with our current re-
sults, antibodies against PD-1 might accelerate the sever-
ity of lupus in vivo by blocking the biological function of
the PD-1 signaling pathway. Controversially, in vivo
blockade of PD-1 receptor in a lupus murine model
(NZB/WF1) has been shown to delay the disease pro-
gression [34–36], and might, owing to the high affinity
and doses of commercial PD-1 antibodies administered
to mice, result in the dissolution of T cells instead of the
inhibition of T cells function.
Despite PD-1 acting as a negative signal for T cell acti-
vation and proliferation, it has been shown that PD-1
signaling is also required for the continued maintenance
of functional Tregs that may control autoimmunity in
lupus-prone mice models [35]. Besides, the expression
level of PD-1 on Tregs was decreased remarkably in SLE
patients compared with healthy donors [14]. The PD-1
pathway and Tregs are both crucial for attenuating im-
mune responses by regulating T cell activation. Confus-
ingly, proportions of Tregs in SLE patients were not
fully confirmed. Numerous studies have found decreased
frequency and defective regulatory function of CD4+
CD25+ Tregs in SLE patients, which is inversely corre-
lated with disease activity (SLEDAI scores) and serum
levels of autoantibody [37–40]. However, unaltered or
increased frequency of Tregs, positively correlated with
the disease activity in SLE patients, has been demon-
strated in some other studies [41, 42]. Thus, more re-
search needs to be done to elucidate the role of PD-1
and Tregs in SLE.
In general, the function of PD-1 autoantibodies in vivo
remains complicated and additional animal studies are
required to elucidate the contribution of PD-1 autoanti-
bodies on immunoregulation function including Tregs
in SLE.
Conclusions
Autoantibodies against PD-1 were significantly high in
the sera of new-onset SLE patients and exacerbated T
cell proliferation via blocking the function of immune
checkpoint PD-1, suggesting that PD-1 autoreactivity
might be a novel pathogenesis contributing to the devel-
opment of SLE.
Additional file
Additional file 1: Figure S1. Serum levels of anti-PD-1 IgG in new-onset
SLE patients classified into four equal groups according to the SLEDAI score.
Values represent the means ± SD. ***p < 0.001. **p < 0.01. *p < 0.05. ns no
significance. (TIF 402 kb)
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